3,6-二乙基-N-(3-戊烷基)-2-吡嗪胺 | 622834-90-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3,6-二乙基-N-(3-戊烷基)-2-吡嗪胺
• 英文名称: N-(1-ethyl)propyl-3,6-diethylpyrazine-2-amine
• 英文别名: 3,6-diethyl-N-(1-ethylpropyl)pyrazin-2-amine；3,6-Diethyl-N-(3-pentanyl)-2-pyrazinamine；3,6-diethyl-N-pentan-3-ylpyrazin-2-amine
• CAS: 622834-90-6
• 化学式: C₁₃H₂₃N₃
• 分子量: 221.346
• InChiKey: REYCUWZDSAQLBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,6-二乙基-N-(3-戊烷基)-2-吡嗪胺 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以85%的产率得到5-bromo-[N-(1-ethyl)propyl]-3,6-diethylpyrazine-2-amine
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZINE DERIVATIVES
  [FR] DERIVES PYRAZINIQUES SUBSTITUES

  摘要：

  本发明提供了式（I）的取代吡嗪衍生物，其为CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及利用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是与焦虑有关的疾病和情绪障碍。

  公开号：

  WO2003091225A1
• 作为产物：
  描述：

  3-氯-2,5-二乙基吡嗪 、 3-氨基戊烷 在 tris-(dibenzylideneacetone)dipalladium(0) 、 2-(二叔丁基膦)联苯 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 4.0h， 以84%的产率得到3,6-二乙基-N-(3-戊烷基)-2-吡嗪胺
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZINE DERIVATIVES
  [FR] DERIVES PYRAZINIQUES SUBSTITUES

  摘要：

  本发明提供了式（I）的取代吡嗪衍生物，其为CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及利用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是与焦虑有关的疾病和情绪障碍。

  公开号：

  WO2003091225A1

文献信息

• Substituted pyrazine derivatives
  申请人：——

  公开号：US20040053941A1

  公开（公告）日：2004-03-18

  The present invention provides substituted pyrazine derivatives of Formula I, 1 that are CRF 1 receptor antagonists, including human CRF 1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

  本发明提供了式I,1的取代吡嗪衍生物，它们是CRF1受体拮抗剂，包括人类CRF1受体。本发明还涉及使用本发明的化合物治疗疾病或症状，其治疗可以通过拮抗CRF受体来实现或促进，例如中枢神经系统疾病，特别是焦虑相关疾病和情绪障碍。
• Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists
  作者：Jeffrey W. Corbett、Mark R. Rauckhorst、Fang Qian、Robert L. Hoffman、Christopher S. Knauer、Lawrence W. Fitzgerald

  DOI：10.1016/j.bmcl.2007.09.008

  日期：2007.11

  Low nanomolar corticotropin releasing factor type-1 (CRF1) receptor antagonists containing unique indanylamines were identified from the heteroatom-linked pyrazine chemotype. The most potent indanylpyrazine had a K-i = 11 +/- 1 nM. The oxygen-linked pyrazinyl derivatives were prepared through a copper-catalyzed coupling of a pyridinone to a bromo- or iodopyrazine. (C) 2007 Elsevier Ltd. All rights reserved.
• Discovery of <i>N</i>-(1-Ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine <b>59</b> (NGD 98−2): An Orally Active Corticotropin Releasing Factor-1 (CRF-1) Receptor Antagonist
  作者：Kevin J. Hodgetts、Ping Ge、Taeyoung Yoon、Stéphane De Lombaert、Robbin Brodbeck、Michael Gulianello、Andrzej Kieltyka、Raymond F. Horvath、John H. Kehne、James E. Krause、George D. Maynard、Diane Hoffman、Younglim Lee、Laurence Fung、Dario Doller

  DOI：10.1021/jm200365y

  日期：2011.6.23

  The design, synthesis, and structure-activity relationships of a novel series of pyrazines, acting as corticotropin releasing factor-1 (CRF-1) receptor antagonists, are described. Synthetic methodologies were developed to prepare a number of substituted pyrazine cores utilizing regioselective halogenation and chemoselective derivatization. Noteworthy, an efficient 5-step synthesis was developed for the lead compound 59 (NGD 98-2), which required no chromatography. Compound 59 was characterized as an orally bioavailable, brain penetrant, and highly selective CRF-1 receptor antagonist. Occupancy of rat brain CRF-1 receptors was quantified using ex vivo receptor occupancy assays, using both brain tissue homogenates as well as brain slices receptor autoradiography. Behaviorally, oral administration of 59 significantly antagonized CRF-induced locomotor activity at doses as low as 10 mg/kg and dose-dependently reduced the restraint stress-induced ACTH increases.
• SUBSTITUTED PYRAZINE DERIVATIVES
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1499599A1

  公开（公告）日：2005-01-26
• US6964965B2
  申请人：——

  公开号：US6964965B2

  公开（公告）日：2005-11-15